DOCSLIB.ORG

List of Restricted and Controlled Drugs Cd(A) [ 2007-2008 ]

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
List of Restricted and Controlled Drugs Cd(A) [ 2007-2008 ] دولة اﻹمارات العربية المتحدة UNITED ARAB EMIRATES وزارة الصحة MINISTRY OF HEALTH إدارة الرقابة الدوائية DRUG CONTROL DEPARTMENT قسم الشؤون الفنية TECHNICAL AFFAIRS SECTION شعبة التسجيل الدوائي و التسعيرة DRUG REGISTRATION AND PRICING UNIT LIST OF RESTRICTED AND CONTROLLED DRUGS CD(A) [ 2007-2008 ] TRADE NAME GENERIC NAME FORM INDICATIONS COMPANY AGENT DISP. REMARKS Modern Bristol Myers 1 ABILIFY 10mg Aripiprazole 10mg Tablets schizophrenia. Pharmaceutical CD (A) Squibb Co. Modern Bristol Myers 2 ABILIFY 15mg Aripiprazole 15mg Tablets schizophrenia. Pharmaceutical CD (A) Squibb Co. Modern Bristol Myers 3 ABILIFY 20mg Aripiprazole 20mg Tablets schizophrenia. Pharmaceutical CD (A) Squibb Co. Modern Bristol Myers 4 ABILIFY 30mg Aripiprazole 30mg Tablets schizophrenia. Pharmaceutical CD (A) Squibb Co. Al INMA Drug Buprenorphine 2 mg sublingual store and 5 Addnok 2mg Opoid analgesic Rusan Pharma Ltd CD (A) / 1 Tablet tablet medical equipments. Gulf Drug Est. 6 ADUMBRAN Oxazepam 10 mg Tablets Anti anxiety CLAG LTD. CD (A) Flumazenil Antidote for 7 ANEXATE 0.5mg/5ml Injection Hoffman La ROCHE Al Razi Pharmacy CD (A) 0.1mg/ml benzodiazepines Page 1 of 49 دولة اﻹمارات العربية المتحدة UNITED ARAB EMIRATES وزارة الصحة MINISTRY OF HEALTH إدارة الرقابة الدوائية DRUG CONTROL DEPARTMENT قسم الشؤون الفنية TECHNICAL AFFAIRS SECTION شعبة التسجيل الدوائي و التسعيرة DRUG REGISTRATION AND PRICING UNIT LIST OF RESTRICTED AND CONTROLLED DRUGS CD(A) [ 2007-2008 ] TRADE NAME GENERIC NAME FORM INDICATIONS COMPANY AGENT DISP. REMARKS Flumazenil Antidote for 8 ANEXATE 1mg/10ml Injection Hoffman La ROCHE Al Razi Pharmacy CD (A) 0.1mg/ml benzodiazepines Misoprostol 0.2mg 9 ARTHROTEC 50 Diclofenac sodium Tablets NSAID'S Searle Pharm. Al Baker Trading CD (A) 50mg Modern Wyeth-Pharma 10 ATIVAN 1 Lorazepam 1mg Tablets Anxiolytic Pharmaceutical CD (A) GmbH Co. Hameln Atracurium-hameln Atracurium besilate Pharmaceuticals 11 10mg/ml Injection ANAESTHESIA Gulf Drug Est. CD (A) (25mg/2.5ml) GmbH[Hameln;GER (25mg/2.5ml) Injection MANY] Hameln Atracurium-hameln Atracurium besilate Pharmaceuticals 12 10mg/ml (50mg/5ml) Injection ANAESTHESIA Gulf Drug Est. CD (A) (50mg/5ml) GmbH[Hameln;GER Injection MANY] Atracurium ABBOTT 13 Atracurium-besylate Dibesylate 10mg/1 Injection ANAESTHESIA LABORATORIES[Ka City Pharmacy CD (A) ml nsas;USA] Sultopride 14 BARNETIL 200mg/2ml Injection Schizophrenia Delagrange Lab. Alphamed CD (A) 200mg/2ml Page 2 of 49 دولة اﻹمارات العربية المتحدة UNITED ARAB EMIRATES وزارة الصحة MINISTRY OF HEALTH إدارة الرقابة الدوائية DRUG CONTROL DEPARTMENT قسم الشؤون الفنية TECHNICAL AFFAIRS SECTION شعبة التسجيل الدوائي و التسعيرة DRUG REGISTRATION AND PRICING UNIT LIST OF RESTRICTED AND CONTROLLED DRUGS CD(A) [ 2007-2008 ] TRADE NAME GENERIC NAME FORM INDICATIONS COMPANY AGENT DISP. REMARKS 15 BARNETIL 400 Sultopride 400mg Tablets Schizophrenia Delagrange Lab. Alphamed CD (A) Prochlorperazine 16 BUCCASTEM 3mg Tablets Nausia and Vomiting Reckitt Benckiser City Pharmacy CD (A) Maleate 3mg Modern Zuclopenhtixol Antipsychotic, 17 CLOPIXOL 2 Tablets Lundbeck Pharmaceutical CD (A) diHCL 2mg Neuroleptic Co. Modern Zuclopenhtixol Antipsychotic, 18 CLOPIXOL 25 Tablets Lundbeck Pharmaceutical CD (A) diHCL 25mg Neuroleptic Co. Modern CLOPIXOL -Acuphase Zuclopenhtixol Antipsychotic, 19 Injection Lundbeck Pharmaceutical CD (A) 100mg acetate 100mg/2ml Neuroleptic Co. Zuclopenhtixol Modern Antipsychotic, 20 CLOPIXOL Depot 200 decanoate Injection Lundbeck Pharmaceutical CD (A) Neuroleptic 200mg/ml Co. Modern Zuclopenhtixol Antipsychotic, 21 CLOPIXOL Depot 500 Injection Lundbeck Pharmaceutical CD (A) acetate 500mg/ml Neuroleptic Co. Modern Zuclopenhtixol Antipsychotic, 22 CLOPIXOL10 Tablets Lundbeck Pharmaceutical CD (A) diHCL 10mg Neuroleptic Co. Page 3 of 49 دولة اﻹمارات العربية المتحدة UNITED ARAB EMIRATES وزارة الصحة MINISTRY OF HEALTH إدارة الرقابة الدوائية DRUG CONTROL DEPARTMENT قسم الشؤون الفنية TECHNICAL AFFAIRS SECTION شعبة التسجيل الدوائي و التسعيرة DRUG REGISTRATION AND PRICING UNIT LIST OF RESTRICTED AND CONTROLLED DRUGS CD(A) [ 2007-2008 ] TRADE NAME GENERIC NAME FORM INDICATIONS COMPANY AGENT DISP. REMARKS Modern CLOPIXOL-Acuphase Zuclopenhtixol Antipsychotic, 23 Injection Lundbeck Pharmaceutical CD (A) 50mg acetate 50mg/ml Neuroleptic Co. Codeine 30mg, 24 CODIPRONT Phenyltoloxamine Capsules Antitussive Heinrich Mack Pharmatrade CD (A) 10mg Codeine 11.1mg , 25 CODIPRONT Phenyltoloxamine Syrup Antitussive Heinrich Mack Pharmatrade CD (A) 3.7mg/5ml Codeine 30mg , Antitussive, 26 CODIPRONT Cum Exp. Tablets Heinrich Mack Pharmatrade CD (A) Phenyltoloxamine Expectorant 10mg,Guaifenesin 27 CYTOTEC Misoprostol 200mcg Tablets Ulcer healing drug Searle Pharm. Al Baker Trading CD (A) Flupentixol diHCL Modern 28 DEANXIT 0.5mg, Melitracene Tablets Antipsychotic Lundbeck Pharmaceutical CD (A) HCL 10mg Co. DEHYDROBENZ- Antipsychotic, 29 Droperidol 2.5mg/ml Injection Janssen Pharm. City Pharmacy CD (A) PERIDOL Neuroleptic New Medical 30 DEMETRIN 10 Prazepam 10mg Tablets Anxiolytic Parke-Davis CD (A) Center Dihydrocodeine 31 DHC CONTINUS Tablets Analgesic Bard Pharm. City Pharmacy CD (A) tartrate 60mg Diazepam Rectal New Medical 32 DIALAG microclysma Anxiolytic Lagap SA CD (A) 5mg/2.5ml solution Center Page 4 of 49 دولة اﻹمارات العربية المتحدة UNITED ARAB EMIRATES وزارة الصحة MINISTRY OF HEALTH إدارة الرقابة الدوائية DRUG CONTROL DEPARTMENT قسم الشؤون الفنية TECHNICAL AFFAIRS SECTION شعبة التسجيل الدوائي و التسعيرة DRUG REGISTRATION AND PRICING UNIT LIST OF RESTRICTED AND CONTROLLED DRUGS CD(A) [ 2007-2008 ] TRADE NAME GENERIC NAME FORM INDICATIONS COMPANY AGENT DISP. REMARKS Diazepam Rectal New Medical 33 DIALAG microclysma Anxiolytic Lagap SA CD (A) 10mg/2.5ml solution Center 34 DIAPAM 10 Diazepam 10mg Tablets Anxiolytic Orion Pharm.Co. Al Hayat Pharm. CD (A) 35 DIAPAM 2 Diazepam 2mg Tablets Anxiolytic Orion Pharm.Co. Al Hayat Pharm. CD (A) 36 DIAPAM 5 Diazepam 5mg Tablets Anxiolytic Orion Pharm.Co. Al Hayat Pharm. CD (A) 37 DIAZEPAM 2 Diazepam 2mg Tablets Anxiolytic Julphar Julphar CD (A) 38 DIAZEPAM 5 Diazepam 5mg Tablets Anxiolytic Julphar Julphar CD (A) Codeine 11mg , Antihistaminic, 39 DICTON retard 30 Carbinoxamine Syrup Dolorgiet Arabian Ethicals CD (A) Antitussive 1.5mg/5ml Modern (Hospital use) 40 DIPRIVAN 1% w/v Propofol 1.00% w/v I.V. Infusion Anaesthetic Astra Zeneca Pharmaceutical CD (A) Co. Modern (Hospital use) 41 DIPRIVAN 2% w/v Propofol 20mg/1ml I.V. Infusion Anaesthetic Astra Zeneca Pharmaceutical CD (A) Co. Sulpiride 100 42 DOGMATIL 100 Injection Schizophrenia Synthelabo Alphamed CD (A) mg/2ml 43 DOGMATIL 25mg/5ml Sulpiride 25mg/5ml Solution Schizophrenia Synthelabo Alphamed CD (A) 44 DOGMATIL 50 Sulpiride 50 mg Capsules Schizophrenia Synthelabo Alphamed CD (A) 45 DOGMATIL Forte Sulpiride 200 mg Tablets Schizophrenia Synthelabo Alphamed CD (A) Page 5 of 49 دولة اﻹمارات العربية المتحدة UNITED ARAB EMIRATES وزارة الصحة MINISTRY OF HEALTH إدارة الرقابة الدوائية DRUG CONTROL DEPARTMENT قسم الشؤون الفنية TECHNICAL AFFAIRS SECTION شعبة التسجيل الدوائي و التسعيرة DRUG REGISTRATION AND PRICING UNIT LIST OF RESTRICTED AND CONTROLLED DRUGS CD(A) [ 2007-2008 ] TRADE NAME GENERIC NAME FORM INDICATIONS COMPANY AGENT DISP. REMARKS 46 DORMICUM 15 Midazolam 15mg Tablets Anxiolytic Hoffman La ROCHE Al Razi Pharmacy CD (A) Midazolam 47 DORMICUM 15mg/3ml Injection Anxiolytic Hoffman La ROCHE Al Razi Pharmacy CD (A) 15mg/3ml 48 DORMICUM 5mg/ml Midazolam 5mg/ml Injection Anxiolytic Hoffman La ROCHE Al Razi Pharmacy CD (A) 49 DORMICUM 7.5mg Midazolam 7.5mg Tablets Anxiolytic Hoffman La ROCHE Al Razi Pharmacy CD (A) Mephenoxalone Modern 50 DORSILON 200mg,Paracetamol Tablets Muscle relaxant Syntex Pharma A.G CD (A) Pharmacy Co. 450mg Modern 51 FLUANXOL 0.25 Flupenthixol 0.25mg Tablets Antidepressant Lundbeck CD (A) Pharmacy Co. Modern 52 FLUANXOL 0.5 Flupenthixol 0.5mg Tablets Antidepressant Lundbeck Pharmaceutical CD (A) Co. Modern 53 FLUANXOL 1 Flupenthixol 1mg Tablets Antidepressant Lundbeck Pharmaceutical CD (A) Co. Modern 54 FLUANXOL 3 Flupenthixol 3mg Tablets Antidepressant Lundbeck Pharmaceutical CD (A) Co. Modern Flupenthixol 55 FLUANXOL Depot Injection Antidepressant Lundbeck Pharmaceutical CD (A) 20mg/ml Co. Page 6 of 49 دولة اﻹمارات العربية المتحدة UNITED ARAB EMIRATES وزارة الصحة MINISTRY OF HEALTH إدارة الرقابة الدوائية DRUG CONTROL DEPARTMENT قسم الشؤون الفنية TECHNICAL AFFAIRS SECTION شعبة التسجيل الدوائي و التسعيرة DRUG REGISTRATION AND PRICING UNIT LIST OF RESTRICTED AND CONTROLLED DRUGS CD(A) [ 2007-2008 ] TRADE NAME GENERIC NAME FORM INDICATIONS COMPANY AGENT DISP. REMARKS Flupentixol Modern 56 FLUANXOL Depot Injection Antidepressant Lundbeck CD (A) decanoate Pharmaceutical Al Ittihad 57 FRISIUM 10 Clobazam 10 mg Tablets Anxiolytic Hoechst CD (A) Pharmacy Al Ittihad 58 FRISIUM 20 Clobazam 20 mg Tablets Anxiolytic Hoechst CD (A) Pharmacy Phenobarbitone May&Baker Rhone- 59 GARDINAL SODIUM Injection Antiepileptic Pharmatrade CD (A) sodium 200mg/ml Poulenc Modern 60 GENPRID 50 Sulpiride 50 mg Tablets Schizophrenia Riyadh Pharma Pharmaceutical CD (A) Co. Modern 61 GENPRID 200 Sulpiride 200 mg Capsules Schizophrenia Riyadh Pharma Pharmaceutical CD (A) Co. Antipsychotic, 62 HALDOL 0.5 Haloperidol 0.5mg Tablets Janssen Pharm. City Pharmacy CD (A) Neuroleptic Antipsychotic, 63 HALDOL 2mg/ml Haloperidol 2mg/ml Drops Janssen Pharm. City Pharmacy CD (A) Neuroleptic Antipsychotic, 64 HALDOL 5 Haloperidol 5mg Tablets Janssen Pharm. City Pharmacy CD (A) Neuroleptic Antipsychotic, 65 HALDOL 5mg/ml Haloperidol 5mg/ml Injection Janssen Pharm. City Pharmacy CD (A) Neuroleptic
Load more

Recommended publications
  • Effect of Intranasal Ketamine Vs Fentanyl on Pain
    1 PROTOCOL SYNOPSIS 2 STUDY TITLE: 3 Pain Reduction with Intranasal Medications for Extremity Injuries (PRIME): A Randomized Clinical 4 Noninferiority Trial of Intranasal Ketamine vs. Fentanyl 5 6 PROTOCOL TITLE 7 Pain Reduction with Intranasal Medications for Extremity injuries (PRIME) 8 9 PRINCIPAL INVESTIGATOR: 10 Theresa M. Frey, MD 11 Assistant Professor Clinical Pediatrics 12 Division of Pediatric Emergency Medicine 13 Cincinnati Children’s Hospital Medical Center 14 513-636-7966 15 [email protected] 16 17 CO-INVESTIGATORS: 18 Matthew R. Mittiga, MD 19 Todd A. Florin, MD, MSCE 20 Michelle C. Caruso, PharmD, BCPS 21 Nanhua Zhang, PhD 22 Yin Zhang, MS 23 24 I. ABSTRACT 25 26 Introduction: Inadequate pain control in the emergency department, particularly in the pediatric 27 population, is a major health concern. The intranasal route of medication administration is gaining 28 popularity secondary to its rapid onset of action, minimal discomfort for the patient and relative 29 simplicity. When pediatric patients present with moderate to severe pain from traumatic injuries, 30 opioids are currently the most frequently used class of analgesia, but they may not always be the best 31 option for numerous reasons. Sub-dissociative dosing of ketamine has been shown to be an effective 32 alternative to opioids in providing adequate pain relief. 33 34 Objectives: The objectives of this study are to 1) determine if intranasal ketamine is non-inferior to 35 intranasal fentanyl in reduction of pain in children presenting with extremity injuries and 2) define and 36 compare the level of sedation and respiratory side effect profile associated with intranasal ketamine and 37 fentanyl.
    [Show full text]
  • Meprobamate Art 107 AR
    30 March 2012 EMA/212617/2012 Assessment report for meprobamate-containing medicinal products for oral use Procedure number: EMEA/H/A-107/1316 Procedure under Article 107 of Directive 2001/83/EC, as amended Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2012. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 3 1.1. Referral of the matter to the CHMP ......................................................................... 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction......................................................................................................... 3 2.2. Discussion on safety ............................................................................................. 4 2.2.1. Non-clinical data ................................................................................................ 4 2.2.2. Clinical safety .................................................................................................... 4 2.2.2.1. Clinical studies ..............................................................................................
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Biased Versus Partial Agonism in the Search for Safer Opioid Analgesics
    molecules Review Biased versus Partial Agonism in the Search for Safer Opioid Analgesics Joaquim Azevedo Neto 1 , Anna Costanzini 2 , Roberto De Giorgio 2 , David G. Lambert 3 , Chiara Ruzza 1,4,* and Girolamo Calò 1 1 Department of Biomedical and Specialty Surgical Sciences, Section of Pharmacology, University of Ferrara, 44121 Ferrara, Italy; [email protected] (J.A.N.); [email protected] (G.C.) 2 Department of Morphology, Surgery, Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy; [email protected] (A.C.); [email protected] (R.D.G.) 3 Department of Cardiovascular Sciences, Anesthesia, Critical Care and Pain Management, University of Leicester, Leicester LE1 7RH, UK; [email protected] 4 Technopole of Ferrara, LTTA Laboratory for Advanced Therapies, 44122 Ferrara, Italy * Correspondence: [email protected] Academic Editor: Helmut Schmidhammer Received: 23 July 2020; Accepted: 23 August 2020; Published: 25 August 2020 Abstract: Opioids such as morphine—acting at the mu opioid receptor—are the mainstay for treatment of moderate to severe pain and have good efficacy in these indications. However, these drugs produce a plethora of unwanted adverse effects including respiratory depression, constipation, immune suppression and with prolonged treatment, tolerance, dependence and abuse liability. Studies in β-arrestin 2 gene knockout (βarr2( / )) animals indicate that morphine analgesia is potentiated − − while side effects are reduced, suggesting that drugs biased away from arrestin may manifest with a reduced-side-effect profile. However, there is controversy in this area with improvement of morphine-induced constipation and reduced respiratory effects in βarr2( / ) mice. Moreover, − − studies performed with mice genetically engineered with G-protein-biased mu receptors suggested increased sensitivity of these animals to both analgesic actions and side effects of opioid drugs.
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • FDA Warns About an Increased Risk of Serious Pancreatitis with Irritable Bowel Drug Viberzi (Eluxadoline) in Patients Without a Gallbladder
    FDA warns about an increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder Safety Announcement [03-15-2017] The U.S. Food and Drug Administration (FDA) is warning that Viberzi (eluxadoline), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. An FDA review found these patients have an increased risk of developing serious pancreatitis that could result in hospitalization or death. Pancreatitis may be caused by spasm of a certain digestive system muscle in the small intestine. As a result, we are working with the Viberzi manufacturer, Allergan, to address these safety concerns. Patients should talk to your health care professional about how to control your symptoms of irritable bowel syndrome with diarrhea (IBS-D), particularly if you do not have a gallbladder. The gallbladder is an organ that stores bile, one of the body’s digestive juices that helps in the digestion of fat. Stop taking Viberzi right away and get emergency medical care if you develop new or worsening stomach-area or abdomen pain, or pain in the upper right side of your stomach-area or abdomen that may move to your back or shoulder. This pain may occur with nausea and vomiting. These may be symptoms of pancreatitis, an inflammation of the pancreas, an organ important in digestion; or spasm of the sphincter of Oddi, a muscular valve in the small intestine that controls the flow of digestive juices to the gut. Health care professionals should not prescribe Viberzi in patients who do not have a gallbladder and should consider alternative treatment options in these patients.
    [Show full text]
  • Use of Chemical Chelators As Reversal Agents for Drug
    (19) TZZ_ _ZZZ_T (11) EP 1 210 090 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/724 (2006.01) A61K 31/194 (2006.01) 18.06.2014 Bulletin 2014/25 A61P 39/04 (2006.01) (21) Application number: 00964006.1 (86) International application number: PCT/EP2000/007694 (22) Date of filing: 07.08.2000 (87) International publication number: WO 2001/012202 (22.02.2001 Gazette 2001/08) (54) USE OF CHEMICAL CHELATORS AS REVERSAL AGENTS FOR DRUG- INDUCED NEUROMUSCULAR BLOCK VERWENDUNG VON CHEMISCHEN CHELATOREN ZUR UMKEHRUNG VON PHARMAKOLOGISCH-INDUZIERTER NEUROMUSKULÄRER BLOCKIERUNG UTILISATION D’AGENTS CHIMIQUES CHELATANTS COMME AGENTS DE NEUTRALISATION DU BLOCAGE NEUROMUSCULAIRE PROVOQUE PAR DES MEDICAMENTS (84) Designated Contracting States: (56) References cited: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU AU-A- 3 662 895 MC NL PT SE • B DESIRE: "Inactivaton of sarin and soman by (30) Priority: 13.08.1999 EP 99306411 cyclodextrins in vitro" EXPERIENTIA, vol. 43, no. 4, 1987, pages 395-397, XP000907287 (43) Date of publication of application: • B. DESIRE: "Interaction of soman with beta- 05.06.2002 Bulletin 2002/23 cyclodextrin" FUNDAMENTAL AND APPLIED TOXICOLOGY, vol. 7, no. 4, 1986, pages 647-657, (73) Proprietor: Merck Sharp & Dohme B.V. XP000911170 2031 BN Haarlem (NL) • C. MAY: "Development of a toxin-binding agent as a treatment for tunicamycinuracil toxicity: (72) Inventors: protection against tunicamycin poisoning of • BOM, Antonius, Helena, Adolf sheep" AUSTRALIAN VETERINARY JOURNAL, Ratho, Midlothian EH28 8NY (GB) vol. 76, no.
    [Show full text]
  • Download PDF File
    Ginekologia Polska 2019, vol. 90, no. 9, 520–526 Copyright © 2019 Via Medica ORIGINAL PAPER / GYNECologY ISSN 0017–0011 DOI: 10.5603/GP.2019.0091 Anti-androgenic therapy in young patients and its impact on intensity of hirsutism, acne, menstrual pain intensity and sexuality — a preliminary study Anna Fuchs, Aleksandra Matonog, Paulina Sieradzka, Joanna Pilarska, Aleksandra Hauzer, Iwona Czech, Agnieszka Drosdzol-Cop Department of Pregnancy Pathology, Department of Woman’s Health, School of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland ABSTRACT Objectives: Using anti-androgenic contraception is one of the methods of birth control. It also has a significant, non-con- traceptive impact on women’s body. These drugs can be used in various endocrinological disorders, because of their ability to reduce the level of male hormones. The aim of our study is to establish a correlation between taking different types of anti-androgenic drugs and intensity of hirsutism, acne, menstrual pain intensity and sexuality . Material and methods: 570 women in childbearing age that had been using oral contraception for at least three months took part in our research. We examined women and asked them about quality of life, health, direct causes and effects of that treatment, intensity of acne and menstrual pain before and after. Our research group has been divided according to the type of gestagen contained in the contraceptive pill: dienogest, cyproterone, chlormadynone and drospirenone. Ad- ditionally, the control group consisted of women taking oral contraceptives without antiandrogenic component. Results: The mean age of the studied group was 23 years ± 3.23. 225 of 570 women complained of hirsutism.
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH PrFLUANXOL® Flupentixol Tablets (as flupentixol dihydrochloride) 0.5 mg, 3 mg, and 5 mg PrFLUANXOL® DEPOT Flupentixol Decanoate Intramuscular Injection 2% and 10% flupentixol decanoate Antipsychotic Agent Lundbeck Canada Inc. Date of Revision: 2600 Alfred-Nobel December 12th, 2017 Suite 400 St-Laurent, QC H4S 0A9 Submission Control No : 209135 Page 1 of 35 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ..................................................................................................10 DRUG INTERACTIONS ..................................................................................................13 DOSAGE AND ADMINISTRATION ..............................................................................15 OVERDOSAGE ................................................................................................................18 ACTION AND CLINICAL PHARMACOLOGY ............................................................19 STORAGE AND STABILITY ..........................................................................................21
    [Show full text]
  • Download Document
    FAM001159-0001 intervals of 4-7 days to usual dose of 75-100 mg Dolmatil® (Sanofi-Synthelabo) ~ 100 rag/5 mL, thioridazine 100 rag/ per course and max. 4 injections; max. duration of daily according to response; CHILD not recom- Tablets, both scored, sulpiride 200 rag, net price ’ net price 300 mL = £7.14. Label: 2 treatment 2 weeks---if maintenance treatment mended 100-tabpack=£13.85;400mg(f/c), 100-tab ! fNote. These suspensions should not be diluted but the necessary change to an oral antipsychotic 2-3 Short-term adjunctive management of severe pack = £36¯29. Label: 2 .: :~t~a preparations may be mixed with each other to days after last injection, or to a longer acting anti- anxiety, 15-20rag daily in divided doses; max. Sulpltil® (Pharmacia) I~ ~0iovid¢ intermediate strengths psychotic depot injection given concomitantly 40 mg daily; CHILD not recommended Tablets, scored, sulpiride 200 rag. Net price 28-tab "ff~-~p, brown, thioridazine (as hydrochloride) with last injection of zuclopenthixol acetate; By deep intramuscular injection, psychoses, mania, pack = £4.29; 112-tab pack = £12.85. Label: 2 ~ff.~5"~mg/5 mL, net price 300 mL = £1.98. Label: 2 CHILD not recommended prochlorperazine mesilate 12.5-25 mg 2-3 times Sulpor® (Rosemont) IPoMI Clopi~ol Acuphase® (Lundbeck) daily; CHILD not recommended Oral solution, sugar-free, lemon- and aniseed-fla. LUOPERAZINE Injection (oily), zuclopenthixol acetate 50 mg/mL. By rectum in suppositories, psychoses, mania, the voured, sulpiride 200 mg/5 mL, net price 150 mL (’~’n~ications: see under Dose; anti-emetic (section Net price I-mL amp = £5.20; 2-mL amp = £10.03 equivalent of prochlorperazine maleate 25 mg 2- = £27.00.
    [Show full text]
  • The Following Studies Received Ethical Approval by Institutional And/Or National Review Committees If Appropriate
    The following studies received ethical approval by institutional and/or national review committees if appropriate. Manchester AVA Spring Meeting April 2017 Cardiovascular findings during pre-anesthetic assessment in dogs undergoing two different pre-anesthetic assessment protocols and usefulness of the diagnostic tests performed S Diez-Bernal1, G Ortiz-Diez2, SP Monteagudo-Franco3, P Ruhi-Velasco4, C Garcia- Echarri4, A Perez-Higueras4, V Salazar-Nussio5. 1Anesthesia Service, University of Bern, Bern, Switzerland; 2Cardiology Service, Alfonso X El Sabio University, Madrid, Spain; 3Diagnostic Imaging Service, Alfonso X El Sabio University, Madrid, Spain; 4Alfonso X El Sabio University, Madrid, Spain; 5Anesthesia Service, Alfonso X El Sabio University, Madrid, Spain. The objectives of this study were to describe cardiovascular abnormalities (CVA) found during pre-anesthetic assessment in dogs in a veterinary teaching hospital and to evaluate the usefulness of the different diagnostic tests performed. One hundred and eight client-owned dogs underwent a basic pre-anesthetic assessment protocol including history, physical examination, hematology and biochemistry performed and evaluated by an anesthesia specialist; and a comprehensive pre-anesthetic assessment protocol that included, in addition to the tests performed in the basic assessment protocol, thoracic radiographs, ECG, and echocardiography evaluated by a licensed veterinarian. CVA were identified in twenty-five of ninety-seven dogs (25.8%) by cardiac auscultation; in 15 dogs (13.9%) by ECG; in 6 dogs (5.6%) by thoracic radiographs; and in 39 dogs (36.1%) by echocardiography (95% of which were diagnosed of chronic valvular heart disease, CVHD). Since CVHD was the cardiovascular condition that showed the highest prevalence, sensitivity, specificity and likelihood ratios of the other performed clinical tests were calculated for the diagnosis of this condition (taking echocardiography as gold standard).
    [Show full text]
  • How to Select Pharmacologic Treatments to Manage Recidivism Risk in Sex Off Enders
    How to select pharmacologic treatments to manage recidivism risk in sex off enders Consider patient factors when choosing off -label hormonal and nonhormonal agents ® Dowden Healthex offenders Media traditionally are managed by the criminal justice system, but psychiatrists are fre- Squently called on to assess and treat these indi- CopyrightFor personalviduals. use Part only of the reason is the overlap of paraphilias (disorders of sexual preference) and sexual offending. Many sexual offenders do not meet DSM criteria for paraphilias,1 however, and individuals with paraphil- ias do not necessarily commit offenses or come into contact with the legal system. As clinicians, we may need to assess and treat a wide range of sexual issues, from persons with paraphilias who are self-referred and have no legal involvement, to recurrent sexual offenders who are at a high risk of repeat offending. Successfully managing sex offenders includes psychological and pharmacologic interven- 2009 © CORBIS / TIM PANNELL 2009 © CORBIS / tions and possibly incarceration and post-incarceration Bradley D. Booth, MD surveillance. This article focuses on pharmacologic in- Assistant professor terventions for male sexual offenders. Department of psychiatry Director of education Integrated Forensics Program University of Ottawa Reducing sexual drive Ottawa, ON, Canada Sex offending likely is the result of a complex inter- play of environment and psychological and biologic factors. The biology of sexual function provides nu- merous targets for pharmacologic intervention, in- cluding:2 • endocrine factors, such as testosterone • neurotransmitters, such as serotonin. The use of pharmacologic treatments for sex of- fenders is off-label, and evidence is limited. In general, Current Psychiatry 60 October 2009 pharmacologic treatments are geared toward reducing For mass reproduction, content licensing and permissions contact Dowden Health Media.
    [Show full text]